Top

Radiation Oncology

Published in:

Open Access 01-12-2013 | Short report

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

Authors: Farkhad Manapov, Susanna Sepe, Maximilian Niyazi, Claus Belka, Godehard Friedel, Wilfried Budach

Published in: Radiation Oncology | Issue 1/2013

Abstract

Background

To identify dose-volume parameters predictive for severity of acute esophagitis (CTC > grade 2) in locally-advanced non small-cell lung cancer (LA-NSCLC) patients treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy (HA-CRT) a retrospective analysis was performed. 88 patients were treated with HA-CRT followed by radical surgery. Predictive power of absolute oesophageal length, absolute and relative oesophageal volume included in the 95%-isodose, patient- and tumor-related factors for severity of acute esophagitis was assessed.

Findings

A total of 82 patients (93%) developed radiation-induced acute esophagitis. Grade 1 was documented in 1 (1%), grade 2 in 55 (67%), grade 3 in 23 (28%) and grade 4 in 3 (4%) patients, respectively. Absolute oesophageal volume included in the 95%-isodose (42.8 Gy) achieved 13.5 cm³ (range: 3 – 29 cm³). Of the tested variables in univariate analysis, absolute oesophageal volume included in the 95%-Isodose was found to be the only significant variable (p = 0.03) predicting severe acute esophagitis (CTC > grade 2). For this volume a gradation scale of the likelihood of severity was built.

Conclusion

Increase of absolute oesophageal volume included in the 95%-isodose correlates with severity of acute esophagitis in LA-NSCLC patients treated with neo-adjuvant concurrent HA-CRT.

Available only for authorised users

Pignon JP, Stewart LA: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer 1996,77(11):2413-2414. 10.1002/(SICI)1097-0142(19960601)77:11<2413::AID-CNCR34>3.0.CO;2-YCrossRefPubMed

Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999,52(2):137-148. 10.1016/S0167-8140(99)00087-0CrossRefPubMed

Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999,340(40):265-271.CrossRefPubMed

Curran WJ Jr, Paulus R, Langer CJ Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011,103(19):1452-1460. 10.1093/jnci/djr325CrossRefPubMedPubMedCentral

Friedel G, Hruska D, Budach W, Wolf M, Kyriss T, Hurtgen M, Eulenbruch HP, Dierkesmann R, Toomes H: Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. Lung Cancer 2000,30(3):175-185. 10.1016/S0169-5002(00)00151-3CrossRefPubMed

Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S, et al.: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998,16(2):622-634.PubMed

Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C, Al-Kamash F, Walles T, Aebert H, Kyriss T, Veit S, Kimmich M, Bamberg M, Kohlhaeufl M, Steger V, Hehr T: Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010,28(6):942-948. 10.1200/JCO.2008.21.7810CrossRefPubMed

Friedel G, Walles TH: Reply to R. Stupp et al. J Clin Oncol 2011,29(5):120. 10.1200/JCO.2010.30.1853CrossRef

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010,28(13):2181-2190. 10.1200/JCO.2009.26.2543CrossRefPubMed

10.

Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D: A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999,52(2):129-136. 10.1016/S0167-8140(99)00093-6CrossRefPubMed

11.

Werner-Wasik M, Paulus R, Curran WJ Jr, Byhardt R: Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 2011,12(4):245-251. 10.1016/j.cllc.2011.03.026CrossRefPubMed

12.

Patel AB, Edelman MJ, Kwok Y, Krasna MJ, Suntharalingam M: Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004,60(4):1106-1112. 10.1016/j.ijrobp.2004.04.051CrossRefPubMed

13.

Hirota S, Tsujino K, Endo M, Kotani Y, Satouchi M, Kado T, Hishikawa Y, Obayashi K, Takada Y, Kono M, Abe M: Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 2001,51(2):291-295. 10.1016/S0360-3016(01)01648-0CrossRefPubMed

14.

De Ruyck K, Sabbe N, Oberije C, Oberije C, Vandecasteele K, Thas O, De Ruysscher D, Lambin P, Van Meerbeeck J, De Neve W, Thierens H: Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011,81(2):537-544. 10.1016/j.ijrobp.2011.03.012CrossRefPubMed

Title: Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy
Authors: Farkhad Manapov
Susanna Sepe
Maximilian Niyazi
Claus Belka
Godehard Friedel
Wilfried Budach
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-8-122

At a glance: The STEP trials

Springer Medicine

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

Abstract

Background

Findings

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Findings

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Equivalence of Gyn GEC-ESTRO guidelines for image guided cervical brachytherapy with EUD-based dose prescription

A novel implementation of mARC treatment for non-dedicated planning systems using converted IMRT plans

Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan

Template-based breast IMRT planning for increased workload efficiency

Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report